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SObjective: Lobectomy with systematic complete mediastinal lymph node dissection is standard surgical treat-
ment for localized non–small cell lung cancer. However, selective mediastinal lymph node dissection based
on lobe-specific metastases (selective dissection) has often been performed. This study was designed to evaluate
the validity of the selective lymph node dissection.
Methods: From 1995 through 2003, 625 patients in our hospital had surgery for complete mediastinal lymph
node dissection and 147 for selective dissection. We evaluated whether selective dissection adversely affected
overall survival. To minimize possible biases due to confounding by treatment indication, we performed a retro-
spective cohort analysis by applying a propensity score. The propensity score was calculated by logistic regres-
sion based on 15 factors available that were potentially associated with treatment indication. Patients were divided
into 4 groups according to quartile, and comparison between selective dissection and complete mediastinal lymph
node dissection was made using propensity score quartile-stratified Cox proportional hazard models.
Results: Comparison of baseline characteristics between patients having selective dissection and patients having
complete mediastinal lymph node dissection according to propensity score quartile supported comparability of
the 2 groups. The 5-year overall survival rates were 76.0% for selective dissection versus 71.9% for complete
mediastinal lymph node dissection. The 5-year survival probabilities stratified by propensity score quartile con-
sistently showed no marked difference. In multivariate models, there was no significant difference between the 2
groups (hazard ratio¼ 1.17, P¼ .500) as also seen in the analysis without propensity score (hazard ratio¼ 1.06;
95% confidence interval, 0.68–1.64; P ¼ .810). Therefore, selective dissection showed no significant impact on
poor survival compared with complete mediastinal lymph node dissection.
Conclusions: Selective lymph node dissection did not worsen the survival of patients with non–small cell lung
cancer. (J Thorac Cardiovasc Surg 2010;139:1001-6)The standard surgical treatment for patients with localized
non–small cell lung cancer (NSCLC) is lobectomy or pneu-
monectomy with complete systematic mediastinal as well as
hilar lymphadenectomy, known as radical complete lymph
node dissection (CD).1,2 However, the significance of lym-
phadenectomy is controversial. Some authors advocate the
benefit of lymphadenectomy on histologic staging of lymph
node spread but found no influence on overall survival (OS)
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The Journal of Thoracic and Carout cancer cells is considered to be futile and can potentially
increase perioperative complications or may require longer
operative times.3-7 In contrast, others claim that lymphade-
nectomy is important for therapeutic purposes as well as
for staging.8-11 Despite this controversy, there have been
only 2 randomized controlled trials (RCTs) comparing CD
with mediastinal lymph node sampling.4,9 Izbicki and col-
leagues4 concluded that there was no difference between
the 2 groups in terms of both disease-free survival and OS.
On the other hand, Wu and associates9 reported that CD
has a prognostic impact on survival. However, these results
are not conclusive because of limited sample size and lack of
intention-to-treat analysis. In this regard, we have to wait for
the results of an ongoing randomized trial (ACOSOG
Z0030) in North America.12
It is clear that the location of primary tumor in the lobes
influences mode and extent of nodal spread.13-15 For exam-
ple, Okada and colleagues13 reported that among patients
with skip N2 metastases (no N1 nodes involved) with an up-
per-lobe lesion, none had positive subcarinal nodes. Only 1
of 13 patients with lower-lobe lesions (7.7%) showed nodaldiovascular Surgery c Volume 139, Number 4 1001
General Thoracic Surgery Ishiguro et al
G
T
S10Abbreviations and Acronyms02CD ¼The Jcomplete lymph node dissectionNSCLC ¼ non–small cell lung cancer
OS ¼ overall survival
PS ¼ propensity score
RCT ¼ randomized controlled trial
SD ¼ selective dissectionFIGURE 1. Presentation of the cohort and inclusion and exclusion criteria
and the number of patients. NSCLC, Non–small cell lung cancer.spread to the upper mediastinum. Okada and colleagues13
suggested that lower mediastinal lymphadenectomy was dis-
pensable if hilar and upper mediastinal nodes were tumor-free
in upper-lobe tumors. For lower-lobe tumors, upper medias-
tinal lymphadenectomy was dispensable when the hilar and
subcarinal nodes were tumor-free. These studies suggest
validity of selective lymphadenectomy based on patterns
of lobe-specific lymph node metastases.
From the above-mentioned data, selective dissection (SD)
has often been performed for patients with no apparent
lymph node metastasis or with poor pulmonary reserve, or
for elderly patients, although there were no predefined crite-
ria for type of lymphadenectomy. It should be noted, how-
ever, that SD is different from lymph node sampling
mentioned above, in that lymph nodes that should be re-
moved according to patterns of lymph node metastases are
radically dissected.
There is currently no evidence from RCTs regarding the
validity of SD compared with CD. Large RCTs would take
a long time and have great cost and therefore cannot be easily
performed. The second best evidence should exist in a retro-
spective study comparing the 2 approaches. However, a seri-
ous concern with a retrospective analysis is that results might
be biased by confounding for patient selection,5,6,10 because
patients with earlier diseases, those with poor pulmonary re-
serve, or elderly patients are likely to receive SD.
To eliminate these biases as much as possible, we con-
ducted a retrospective cohort analysis using a propensity
score (PS) to evaluate validity of SD compared with CD.
A PS is defined as the conditional probability of exposure
to a treatment given preoperatively observed covariates. Hy-
pothetically, patients with the same PS have the same prob-
ability of receiving SD or CD. Therefore, patients receiving
SD and patients receiving CD with the same PS provide sim-
ilar comparability. Hence, results obtained by a retrospective
study using a PS are assumed almost similar to those ob-
tained by prospective RCT.16
PATIENTS AND METHODS
Patients
Approval for this study was obtained from and the need for individual
patient consent was waived by the institutional review board. From 1995
through 2003, 893 patients with NSCLC had pulmonary resection at the De-
partment of Thoracic Surgery, Aichi Cancer Center Hospital. Of them, 772ournal of Thoracic and Cardiovascular Surpatients had potentially curative lobectomy, bilobectomy, or pneumonec-
tomy, excluding 121 patients who had lesser resection (partial resection,
segmentectomy, lobectomy without mediastinal node dissection, as shown
in Figure 1). Patients who had neoadjuvant or adjuvant treatment were also
excluded from this study.
Surgical Technique
Surgical techniques for resection of affected lobes were the same in both
groups, consisting either of lobectomy, bilobectomy, or pneumonectomy.
Tumors that exhibited adherence to neighboring structures were treated
by extended resections with en bloc removal of the lobe or lung with adja-
cent organs. Locations of lymph nodes were described according to the
lymph node map for lung cancer described by Naruke and associates.17
In the CD group, resection was combined with a radical systematic en
bloc mediastinal lymphadenectomy as described by Naruke and colleauges1
and Martini and coworkers.2
In the SD group, lymph node dissection was performed based on patterns
of lobe-specific lymph node metastases. When the tumor was located in the
right upper lobe, the upper mediastinal lymph nodes (superior mediastinal
nodes, paratracheal nodes, pretracheal nodes, and tracheobronchial nodes)
were systematically removed. When the tumor was located in the left upper
lobe, aortopulmonary window nodes and aortic nodes in addition to tracheo-
bronchial nodes were resected. In these cases, dissection of lower mediasti-
num was not performed when the nodes in both the hilum and the upper
mediastinum or aortic nodes were free from metastases as shown by intra-
operative diagnosis. Intraoperative frozen section analyses were performed
when lymph node metastases were suspected macroscopically, and when
positive, all patients had CD. Alternatively, when the tumor was located
in the lower lobe, subcarinal and lower mediastinal nodes were dissected,
and dissection of the superior mediastinum was omitted when the intraoper-
ative diagnosis was negative. By such definition, 625 patients belonged to
the CD group and 147 to the SD group. All operations were performed
via thoracotomy.
Pre- and Postoperative Measurements
Survival was determined by institutional database, which is updated with
an annual institutional census or each patient visit. Serum carcinoembryonic
antigen levels were measured using a chemiluminescent immunoassay kit
(Abbott, Tokyo, Japan). Blood gas analyses were performed during rest
in room air. Clinical and postsurgical staging was determined according
to the TNM classification of the International Union Against Cancer.18 Spi-
rometry testing was performed by medical technicians of the specialty using
a spirometer. Trained medical staff asked about smoking history in detail,gery c April 2010
TABLE 1. Covariates that are considered to concern selection of the
types of lymph node dissection
Covariates Category
Age at diagnosis (y) <40, 40–59, 60–69, and 70
Sex Male vs female
CEA at diagnosis Continuous value
Arterial blood gas
PaO2, PaCO2 Continuous value
Pulmonary function
% VC,% FEV1.0,% DLCO,
and FEV1.0
Continuous value
Clinical stage
T factor, N factor Ordinal variable
Smoking index Continuous value
Histologic type Adeno, squamous, and others
Operator Surgeon 1, 2, 3, and 4
Operative procedures Lobectomy, extended lobectomy,
bilobectomy, and pneumonectomy
CEA, Carcinoembryonic antigen; DLCO, diffusing capacity for carbon monoxide;
FEV 1.0, forced expiratory volume in 1 second; VC, vital capacity.
TABLE 2. Patient characteristics
Variables CD (%) SD (%) P value
All patients 625 147
Sex
Male 390 (62) 84 (57) .22*
Female 235 (38) 63 (43)
Age (y) 19–80
(median 62)
34–82
(median 69)
.0001y
Clinical stage
IA 276 (44) 94 (64) .0001*
IB 182 (29) 46 (31)
IIA 7 (1) 0 (0)
IIB 73 (12) 6 (4)
IIIA 76 (12) 1 (1)
IIIB 11 (2) 0 (0)
Histology
AD 436 (70) 117 (80) .02*
SQC 128 (20) 16 (11)
Others 61 (10) 14 (9)
Operation
Lobectomy 522 (84) 140 (95) .002*
Bilobectomy/
pneumonectomy/
extended lobectomy
66 (11) 6 (4)
Lobectomy with adjacent
organ resection
37 (5) 1 (1)
Operator
1 189 (30) 51 (35) .001*
2 149 (24) 15 (10)
3 264 (42) 79 (54)
4 23 (4) 2 (1)
CD, Complete dissection; SD, selective dissection; AD, adenocarcinoma; SQC, squa-
mous cell carcinoma. *Fisher exact test or chi-square test. yWilcoxon rank-sum test.
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years of smoking, was recorded. Resected specimens were examined histo-
pathologically, and histologic classification was performed according to the
World Health Organization classification as shown in Table 1.19
Statistical Methods
Propensity score calculation. We calculated the PS using logistic
regression based upon factors available that were thought to be potentially
associated with patient selection,20 using the pscore command in STATA
version 10 (STATA, College Station, Tex).21 Fifteen such factors included
for calculation of the PS are summarized in Table 1. The number of blocks in
the PS calculation was set as 5. After the calculation of their PS, subjects
were divided into 4 groups according to quartile.
Survival analysis. Our primary end point was OS, which was defined
as the interval between the date of operation and final date of observation or
date of death. Comparison of the CD and SD groups was conducted using
a log-rank test and a Cox proportional hazard model coupled with forward
stepwise covariate selection (threshold P values for removal and inclusion
were .20 and .10, respectively) with stratification by PS quartile. The latter
aimed to remove residual confounding after PS stratification. Factors exam-
ined in the stepwise Cox proportional hazard model were the 15 factors used
to calculate PS (Table 1). Comparison of baseline characteristics between
SD and CD were examined by the Wilcoxon rank sum test for continuous
variables and the Fisher exact test or chi-square test for categorical variables
as appropriate. All survival analyses were conducted with STATA version
10.21
A total of 772 subjects provided statistical power of more than 88%
(1-sided a ¼ .05) and 80% (2-sided a ¼ .05) to detect a 0.3 difference in
the hazard ratio of SD relative to CD, when final failure probability was as-
sumed to be 40%.
RESULTS
Characteristics of subjects in the CD and SD groups are
shown in Table 2. Younger patients, patients in earlier
stages, patients with adenocarcinoma, and those who had lo-
bectomy were more frequently observed in the SD group, as
expected. Therefore, one may assume that direct comparison
between SD and CD may be confounded by patients’The Journal of Thoracic and Cartreatment indication based upon background characteristics.
Table 3 shows a comparison of these characteristics between
CD and SD according to PS quartile. The number of subjects
in quartiles 1, 2, 3, and 4 according to the mode of lymph
node dissection (CD; SD) were (188; 5), (172; 21), (157;
36), and (108; 85), respectively. This demonstrates equiva-
lent distribution of background characteristics in each PS
quartile between the 2 groups, except that age at operation
was significantly higher in the SD group in the highest quar-
tile group.
Figure 2 shows OS after surgery for the CD and SD groups.
The 5-year survival probabilities were 71.9% (95% confi-
dence interval [CI]: 68.0–75.5) for the CD group and 76.0%
(95% CI: 65.3–83.9) for the SD group. There was no signifi-
cant difference in OS between the 2 groups (P¼ .29) without
stratification by PS. After consideration of PS, difference in
survival between the 2 groups was decreased (P ¼ .8098).
The 5-year survival probabilities stratified by PS quartile are
shown in Table 4. This also indicates that the 5-year OSs are
consistently comparable across each PS quartile.
In the Cox proportional hazard model not considering PS,
a crude hazard ratio (HR) for SD relative to CD was 1.06diovascular Surgery c Volume 139, Number 4 1003
TABLE 3. Patient characteristics stratified by PS quartile
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Variables CD SD P value CD SD P value CD SD P value CD SD P value
No. of patients 188 5 172 21 157 36 108 85
Sex
Male 139 5 .186* 101 12 .890* 87 18 .556* 64 49 .821*
Female 49 0 71 9 70 18 44 36
Age (y), median 58 59 .773y 59 57 .446y 63 61 .803y 70 73 <.001y
Clinical stage
IA 23 1 .876* 83 10 .885* 95 26 .417* 75 57 .993*
IB 33 1 60 9 57 9 32 27
IIA 4 0 3 0 0 0 0 0
IIB 42 2 25 2 5 1 1 1
IIIA 76 1 0 0 0 0 0 0
IIIB 10 0 1 0 0 0 0 0
Histology
AD 92 4 .356* 125 17 .517* 128 17 .765* 91 66 .428*
SQC 66 1 34 2 20 2 8 8
LA 30 0 13 2 9 2 9 11
Operation
Lobectomy 115 3 1.0* 149 20 .500* 152 35 .895* 106 82 .767*
Bilobectomy/
pneumonectomy/
extended lobectomy
42 1 17 1 5 1 2 3
Lobectomy with
adjacent organ
resection
31 1 6 0 0 0 0 0
Operator
1 43 0 .528* 51 6 .987* 53 15 .832* 42 30 .447*
2 64 2 63 8 22 4 0 1
3 69 3 51 6 78 16 66 54
4 12 0 7 1 4 1 0 0
PS, Propensity score; CD, complete dissection; SD, selective dissection; AD, adenocarcinoma; SQC, squamous cell carcinoma; LA, large cell carcinoma. *Fisher exact test or chi-
square test. yWilcoxon rank-sum test.
FIGURE 2. Unadjusted overall survival curves of patients stratified by the
type of mediastinal dissection (crude).
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S(95% confidence interval, 0.68–1.64; P ¼ .810). Results of
stepwise multivariate analyses adjusted by PS are shown in
Table 5. Similar to the crude model, no significant risk
change was observed in final multivariate model (HR ¼
1.17; 0.74–1.85, P ¼ .500). Other factors significantly asso-
ciated with poor prognosis in the model were pathologic N
score (2.12 for 1 unit increase, P<0.001) and T score (HR
¼ 1.32 for 1 unit increase,P¼ .006), histology other than ad-
enocarcinoma and squamous cell carcinoma (HR¼ 2.63 rel-
ative to adenocarcinoma, P< 001), age (1.72 for 1 age
category increase, P< .001), percent diffusing capacity for
carbon monoxide (0.99 for 1 unit increase, P¼ .037), and lo-
bectomy with adjacent organ resection (HR ¼ 2.26 relative
to lobectomy, P ¼ .004). Therefore, considering propensity
to SD and impact of other prognostic factors, SD showed no
significant impact on poor survival compared with CD.
Table 6 shows comparisons of operative time, blood loss,
and length of hospital stay in all patients and in those who
had muscle-sparing thoracotomy. For patients with SD, op-
erative time was shorter (202 minutes for CD vs 169 minutes
for SD), blood loss was smaller (220 g for CD vs 65 g for1004 The Journal of Thoracic and Cardiovascular SurSD) and length of hospital stay was shorter (15 days vs 13
days). When we limited the analysis to patients who had
muscle-sparing thoracotomy, eliminating those who had bi-
lobectomy and pneumonectomy, there were also significant
differences for each measurement.gery c April 2010
TABLE 4. The 5-year survival probabilities stratified by PS quartile
CD SD
5-year survival
(95% CI)
5-year survival
(95% CI) P value
Total 71.9% (68.0–75.5) 76.0% (65.3–83.9) .29
Quartile 1 52.3% (44.0–59.9) 60.0% (12.6-88.2) .83
Quartile 2 74.8% (66.9–81.1) 73.8% (24.4–93.7) .36
Quartile 3 83.9% (76.6–89.0) 81.1% (62.5–91.9) .55
Quartile 4 78.3% (68.8–85.2) 74.9% (60.1–84.9) .56
PS, Propensity score; CD, complete dissection; SD, selective dissection.
TABLE 5. A final stepwise multivariate analysis model for overall
survival
Factor HR P value 95% LCI 95% UCI
Lymph node
dissection
(selective vs
complete)
1.17 .500 0.71 1.79
pN (continuous) 2.12 <.001 1.80 2.50
pT (continuous) 1.32 .006 1.08 1.60
Pathology
Adenocarcinoma 1.00
Squamous cell
carcinoma
1.14 .523 0.76 1.71
Others 2.63 <.001 1.74 3.98
Age categories (70–,
60–69, 40–59, and
40–)
1.72 <.001 1.39 2.12
% DLCO
(continuous)
0.99 .037 0.99 1.00
Operation
Lobectomy 1.00
Middle lobe
lobectomy
0.81 .562 0.39 1.68
Bilobectomy/
pneumonectomy/
extended
lobectomy
1.19 .426 0.77 1.83
Lobectomy with
adjacent organ
resection
2.26 .004 1.23 3.74
PaCO2 (continuous) 1.00 .063 1.00 1.01
HR, Hazard ratio; LCI, lower confidence interval; UCI, upper confidence interval;
DLCO, diffusing capacity for carbon monoxide.
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SDISCUSSION
To date, a number of retrospective or prospective studies
for assessment of mediastinal lymph node dissection (CD or
sampling) have been performed.3-15 Two prospective RCTs
compared CD with sampling,4,9 but the results were not con-
sistent and the question whether mediastinal lymphadenec-
tomy improved survival was still unresolved.
Several investigators reported that there were distinct pat-
terns of metastatic lymphatic spread based on location of the
primary tumors. Watanabe and colleagues14 reported that
the metastatic prevalence of patients with pN2 nodes where
no N1 nodes were involved was 7% to 11% from upper-
lobe tumors to the lower part of the mediastinum. Asamura
and colleagues15 found that the most common site of metas-
tasis for tumors with pN2 located in right upper lobe or
tumors in the left superior division was the superior medias-
tinal station, whereas metastases to the subcarinal station
were seen in only 12% to 13% of cases. Indeed, they pro-
posed that subcarinal lymphadenectomy is not always neces-
sary for tumors located there.15 There is a report that
suggests that 3 stations (10, 11, or 12) of N1 lymph nodes
or 1 station of N2 nodes (4 for upper-lobe tumors, 5 for
left upper-lobe tumors, and 7 for lower-lobe tumors) are sen-
tinel lymph nodes of lung cancer like in breast cancer.5
Based on these reports, we take lobe-specific lymph node
metastases into consideration for omitting lymph node dis-
section. Besides, patients with unusual lymph node metasta-
ses (ie, patients with subcarinal metastases from upper-lobe
tumor, or patients with superior mediastinal metastases from
lower-lobe tumor) generally had very poor outcome even
when these lymph nodes were systematically dissected.TABLE 6. Intraoperative parameters
All patients (n)
Operative time, min (range) 2
Blood loss, g (median range)
Length of stay, d (median range)
Anteroaxillary thoracotomy, vertical muscle-sparing thoracotomy (n)
Operative time, min (range) 1
Blood loss, g (median range)
Length of stay, days (median range)
Patients who received lobectomy only (except bilobectomy, pneumonectomy or more). *U
The Journal of Thoracic and CarFor example, Asamura and associates15 reported that right
lower-lobe tumors with superior mediastinal metastasis
carried a particularly poor 5-year survival of only 4.1%.
From the above-mentioned data, SD has been often per-
formed by Japanese surgeons especially when the patients
were of poor risk and had earlier diseases. In addition, prog-
nostic difference between CD and SD is expected to be even
smaller than that between CD and sampling. Okada and
colleagues5 reported that SD did not worsen prognosis of
patients with clinicosurgical stage I NSCLC in their retro-
spective analysis. The 5-year OS rate was 79.7% for CDCD SD P value
625 147
01.9  54.7 (97–482) 169.3  52.2 (90–441) <.001*
220 (15–1445) 65 (10–1630) <.001y
15 (6–346) 13 (8–117) <.001y
410 121
92.1  48.9 (97–405) 163.3  44.4 (90–371) <.001*
110 (15–1170) 65 (10–770) <.001y
15 (6–151) 13 (8–117) <.003y
npaired t test. yMann–Whitney U test.
diovascular Surgery c Volume 139, Number 4 1005
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section did not affect OS in the multivariate analysis. How-
ever, histologically controlled studies have inherent
potential biases in nature.
In this study, we used PS to eliminate such biases as much
as possible. We found that there was no significant differ-
ence in terms of OS between the 2 groups. However, we
admit that the number of covariates to calculate PS was lim-
ited. It is clear that firm conclusions must await an ade-
quately designed RCT whose results would be the most
important evidence for supporting SD. However, this RCT
is almost impossible, and therefore the carefully designed
analysis presented here is of great importance.
We also showed that patients who had SD also had signif-
icantly shorter operative time, less blood loss, and shorter
hospital stay than those who had CD, indicating that SD is
less invasive than CD. Okada and associates5 reported the
morbidity rates (dysrhythmia, pneumonia, prolonged air
leak, chylothorax, etc) were significantly less for patients
with SD (17.3% for CD vs 10.1% for SD, P ¼ .005).
In conclusion, SD did not have significantly impact poor
survival compared with CD by our analysis applying PS. In
addition, it was suggested that SD was associated with less
invasiveness. From the practical point of view, it is reason-
able to perform SD especially for patients with no apparent
lymph node metastases, those with poor pulmonary reserve,
or elderly patients.References
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